Cancer Research and Treatment

Original Articles

Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer: Jun Hwa Lee, Yun Hwan Kim, Kyung-Hee Kim, Jae Youl Cho, Sang Myung Woo, Byong Chul Yoo, Seung Cheol Kim; Cancer Res Treat. 2018;50(3):883-893. Published online September 18, 2017; DOI: https://doi.org/10.4143/crt.2017.275

Abstract PDF Supplementary Material PubReader ePub

Purpose
We sought to develop a matrix assisted laser desorption ionization-time of flight (MALDI-TOF)-based, ovarian cancer (OVC), low-mass-ion discriminant equation (LOME) and to evaluate a possible supportive role for triple-TOF mass analysis in identifying metabolic biomarkers.
Materials and Methods
A total of 114 serum samples from patients with OVC and benign ovarian tumors were subjected to MALDI-TOF analysis and a total of 137 serum samples from healthy female individuals and patients with OVC, colorectal cancer, hepatobiliary cancer, and pancreatic cancer were subjected to triple-TOF analysis. An OVC LOME was constructed by reference to the peak intensity ratios of discriminatory low-mass ion (LMI) pairs. Triple-TOF analysiswas used to select and identify metabolic biomarkers for OVC screening.
Results
Three OVC LOMEs were finally constructed using discriminatory LMI pairs (137.1690 and 84.4119 m/z; 496.5022 and 709.7642 m/z; and 524.5614 and 709.7642 m/z); all afforded accuracies of > 90%. The LMIs at 496.5022 m/z and 524.5614 m/z were those of lysophosphatidylcholine (LPC) 16:0 and LPC 18:0. Triple-TOF analysis selected seven discriminative LMIs; each LMI had a specificity > 90%. Of the seven LMIs, fourwith a 137.0455 m/z ion atretention times of 2.04-3.14 minuteswere upregulated in sera from OVC patients; the ion was identified as that derived from hypoxanthine.
Conclusion
MALDI-TOF–based OVC LOMEs combined with triple-TOF–based OVC metabolic biomarkers allow reliable OVC screening; the techniques are mutually complementary both quantitatively and qualitatively.

Citations

Citations to this article as recorded by

Detection of Protein and Metabolites in Cancer Analyses by MALDI 2000–2025
Dorota Bartusik-Aebisher, Daniel Roshan Justin Raj, David Aebisher
Cancers.2025; 17(21): 3524. CrossRef
Preliminary Metabolomics Study Suggests Favorable Metabolic Changes in the Plasma of Breast Cancer Patients after Surgery and Adjuvant Treatment
Andrea Jiménez-Franco, Juan Manuel Jiménez-Aguilar, Marta Canela-Capdevila, Raquel García-Pablo, Helena Castañé, Cristian Martínez-Navidad, Pablo Araguas, Bárbara Malavé, Rocío Benavides-Villarreal, Johana C. Acosta, Alina Iuliana Onoiu, Navita Somaiah, J
Biomedicines.2024; 12(10): 2196. CrossRef
Circulating proteins as predictive and prognostic biomarkers in breast cancer
Hugo Veyssière, Yannick Bidet, Frederique Penault-Llorca, Nina Radosevic-Robin, Xavier Durando
Clinical Proteomics.2022;[Epub] CrossRef
Applications of MALDI-MS/MS-Based Proteomics in Biomedical Research
Laura Darie-Ion, Danielle Whitham, Madhuri Jayathirtha, Yashveen Rai, Anca-Narcisa Neagu, Costel C. Darie, Brînduşa Alina Petre
Molecules.2022; 27(19): 6196. CrossRef
Methylglyoxal Adducts Levels in Blood Measured on Dried Spot by Portable Near-Infrared Spectroscopy
Giuseppe Bonapace, Francesco Gentile, Nicola Coppedé, Maria Laura Coluccio, Virginia Garo, Marco Flavio Michele Vismara, Patrizio Candeloro, Giuseppe Donato, Natalia Malara
Nanomaterials.2021; 11(9): 2432. CrossRef
Identification of New Peptide Biomarkers for Bacterial Bloodstream Infection
Yating Ma, Xinyu Wen, Yi Kong, Chen Chen, Ming Yang, Shang He, Jianan Wang, Chengbin Wang
PROTEOMICS – Clinical Applications.2020;[Epub] CrossRef
Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis
Kexin Li, Yuqing Pei, Yue Wu, Yi Guo, Wei Cui
Journal of Ovarian Research.2020;[Epub] CrossRef
Comparative cerebrospinal fluid metabolites profiling in glioma patients to predict malignant transformation and leptomeningeal metastasis with a potential for preventive personalized medicine
Ji Hye Im, Byong Chul Yoo, Jun Hwa Lee, Kyung-Hee Kim, Tae Hoon Kim, Kyue-Yim Lee, Jong Heon Kim, Jong Bae Park, Ji-Woong Kwon, Sang Hoon Shin, Heon Yoo, Ho-Shin Gwak
EPMA Journal.2020; 11(3): 469. CrossRef
Exploring Serum Metabolic Markers for the Discrimination of Ccrcc From Renal Angiomyolipoma By Metabolomics
Mingfeng Xiang, Feng Du, Jing Dai, Ling Chen, Ruijin Geng, Huiming Huang, Baogang Xie
Biomarkers in Medicine.2020; 14(8): 675. CrossRef
Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?
Igor Govorov , Stanislav Sitkin , Tatyana Pervunina , Alexey Moskvin , Denis Baranenko , Eduard Komlichenko
Current Medicinal Chemistry.2020; 27(22): 3611. CrossRef

13,948 View
254 Download
11 Web of Science
10 Crossref

Clinico - pathological Study of Endometrial Cancer in Seoul National University Hospital: Soon Beom Kang, Dong Geun Chung, Seung Cheol Kim, Hyo Pyo Lee, Myon Woo Shin; J Korean Cancer Assoc. 1988;20(2):160-172.

Abstract PDF: Clinical and pathological studies were performed on 56 patients with endometrial cancer who were diagnosed and treated in the Department of OB/GY of Seoul National University Hospital from Jan. 1975 ta Dec. 1986. The results were as follows; 1) Of 56 cases, 17 (30.4%) were in stage la, 22 (39.3%) in stage Ib, 5 (8.9%) in stage II, 10 (17.9%) in stage III, and 2 (3.6%) in stage IV according to FIGO classification. 2) The average age was 54.2 and the range 28 to 73. 3) Forty two (75.0%) patients were postmenopausal and the average menopausal age was 49.8 years. 4) All cases except two were symptomatic and in 51 (91.9%) cases, abnormal vaginal bleeding was noted as a chief complaint. 5) The major complications were obesity (37.5%), hypertension (48.2%), diabetes mellitus (16.1%), and irifertility (23.2%). In 5 cases (8.9%), obesity, hypertension, and diabetes mellitus were complicated at the same time. 6) When the depth of the invasion was classified into 3 grades, less than 1/3 of the muscular layer, between 1/3 and 2/3, and over 2/3 in 52 cases examined, they were observed in 15 (2S.8%), 9 (17.3%), 14 cases (26.9%) respectively. And in 14 cases (26.9%), there was no myometrial invasion and the cancer was limited within the endometrium. 7) There were 2 cases (11.1%) with lymph node involvement in 18 cases examined. In one case, the depth of myometrial invasion was less than I/3, and in another case, the depth of invasion was over 2/3. And the histological grade of these cases was G2 in both. 8) The three year survival rate was 69.7% (23/33) for all cases. The clinical stage and age of the patients may be correlated with t.he prognosis of the endometrial cancer (p<0.05). 9) The three year survival rate for the group treated by surgical treatment with pelvic lymph node dissection was 100% (9/9) which was significantly higher than the 68.2% (15/22) of the group treated by simple hysterectomy (p<0.05). We can think that the effort to diagnose the endometrial cancers in the earlier clinical stages and the surgical treatment with pelvic lymph node dissection may improve the prognosis of the endometrial cancer.

2,607 View
22 Download

신피막하 종양이식 분석법에 의한 부인과악성 종야의 화학감수성 검사에 관한 연구: Soon Beom Kang, Kyeong Hoon Cho, Pil Ryang Lee, Seung Cheol Kim, Young Min Choi, Hyo Pyo Lee, Dong Geun Chung, Noe Kyeong Kim, Jae Gahb Park, Seong Hoe Park; J Korean Cancer Assoc. 1990;22(1):24-32.

Abstract PDF: The chemosensitivity testing is important in the research of cancer biology, development and screening of anticancer drug, and improvement of chemotherapy modalities. Subrenal capsule tumor implant assay (SRCA) is a promising rapid method in the selection of individual chemotherapy for cancer patients clinically. A total of 100 SRCA were performed with several gynecologic malignancies(69 cervical, 10 ovarian, 10 endometrial carcinomas, 6 vulva carcinoma, 4 sarcoma, and 1 choriocarcinoma). 1 mm x 1 mm x 1 mm fragments oi fresh human gynenologic tumors were implanted under the renal capsule of immunocompetent female adult BALB-C mice and tested against several chemotherapeutic agents or their combinations. An average of 75% of tumors showed positive growth. The evaluable assay rate was 91%(91/100). Variable response rate were noted in each gynenologic tumor. An overall predictive accuracy rate of SRCA was 73% in present series. In conclusion, the SRCA is considered as a reliable in vivo clinical chemosensitivity test in the selection of individual cancer chemotherapy.

3,023 View
18 Download

First
Prev
Page of 1
Next
Last

Search